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Abstract
Traumatic brain injury (TBI) is the leading cause of mortality and morbidity
especially in young ages, while over 30 years of neuroprotective agents use for TBI
management provided neither any recommended agent for favorable outcome nor
less adverse effects in TBI management yet. This review got selected keywords’
search and ran in known international and local databases, with no limitation up to
September 6, 2015. Related to the subject, clinical human studies have been selected
for the review. Data from 32 studies were classified into 10 subgroups. About 18
studies with a population of 4637 participants were included in 6 topic reviews and
meta-analyses. Oxygen use in acute management of TBI to reduce mortality rates
could be recommended. Corticosteroid use in solo acute TBI management is
prohibited due to increasing risk of mortalities. However, in dual-diagnosed
patients (TBI and spinal cord injury (SCI) together), corticosteroid use should be
obtained by a Bracken protocol. The use of citicoline in acute TBI is no more
supported. The use of cyclosporine-A for ICP control depends on the resources and
physician’s decision. Rivastigmine use for chronic neurocognitive conditions of TBI
management had some beneficence in severely impaired participants. However, the
use of other agents in TBI has no field of support yet.
Keywords: traumatic brain injury, head injury, neuroprotective agents,
systematic review, meta-analysis
1. Introduction
1.1 Description of the condition
Traumatic brain injury (TBI), which is also known as head injury [1–3], is the
leading cause of mortality and morbidity [1, 4–6], especially in young ages [1]; that
is defined as “the occurrence of injury to the head, that is, associated with symp-
toms or signs attributable to the injury such as decreased level of consciousness,
amnesia, other neurological or neuropsychological abnormalities, skull fracture,
intracranial lesions or death.” [6].
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Epidemiological studies, demonstrate following statements in USA [4];
• The incidence rate of 558 cases per 100,000 person each year,
• TBI related disability estimated as 33 new cases per 100,000 people in a year,
• More than 50,000 deaths each year,
• Motor vehicle collisions (MVC) is the responsible for 50% of TBI causes,
following by falls (38%), and violence (also including attempted suicide) 4%,
• TBI costs more than $48 billion a year. About 2.5 and 6.5 million Americans
alive today have had a TBI assault. “Survivors of TBI are often left with
significant cognitive, behavioral, and communicative disabilities” [7].
According to the chronology period and the state of the condition, it
categorizes under “Primary” and “Secondary” injury [1].
1.2 Description of the intervention
According to medical subheadings (MeSH) definition, Neuroprotective agents
are “Drugs intended to prevent damage to the brain or spinal cord from ischemia,
stroke, convulsions, or trauma. Some must be administered before the event, but
others may be effective for some time after. They act by a variety of mechanisms,
but often directly or indirectly minimize the damage produced by endogenous
excitatory amino acids” [8]. As mentioned in the MeSH definition, there are variety
of drugs and their action mechanisms to minimize the TBI damage; the breadth list
of trials on www.clinicaltrial.gov for “Neuroprotective Agents” and “Traumatic
Brain Injury” terms, states this. A recent study of Burns et al. declared 30 years of
using Neuroprotective agents on animal models forecasting the same effect on
humans failed, and represents to use animal models as new cases for stem cell
studies as well, rather than formerly known for using Neuroprotective agents [9],
which is confirmed by other studies too [10, 11].
The recent challenging review and meta-analyses study of Leucht et al. about
efficacy of commonly used major drugs for medical and psychological conditions,
seems to be a practice-challenging article for all physicians over the world [12]; this
meta-analyzed article’s results on major commonly used drugs showed the small to
medium effect of 13 drugs and nearly medium to favorable effect of 3 drugs out of
19 major commonly used drugs for variety of clinical or mental conditions;
collecting these information together rings a bell; how to use the most effective
interventions for conditions?
2. Literature review
There are wide variety of Neuroprotective agents, and breadth studies on human
and animal cases, the following lists the agents which were studied on human
clinical trials:
2.1 Oxygen
The vital element of life and viability of neurons. Hypoxia leads to anaerobic
metabolism, acidosis, and reduction in cellular metabolism. Neurons messaging
conduction ability disturbs due to loss of their ability to maintain ionic homeostasis.
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Free oxygen radicals also accumulate and degrade cell membrane; which all if lead
to irreversible changes in neuron cells, it “results in unavoidable cell death.” There
are also Cochrane reviews for hyperbaric oxygen (HBO2) and hyperventilation
(NBH) use in TBI [1, 2].
2.2 Corticosteroids
Inflammatory process after TBI, which causes brain edema and intracranial
pressure (ICP) rise, performed the hypothesis of using corticosteroids for TBI, the
primary researches and studies showed the beneficial effect of this intervention,
while CRASH trial in 2005 and an updated Cochrane review after that, challenged
the efficacy of corticosteroids use for TBI [4]; further from this study’s proposal,
steroids using for spinal cord injury (SCI) seems to have beneficial effects; also
there is a Cochrane review for its neuroprotection beneficence in SCI assaults [13].
2.3 Progesterone
It has a wide variety of neuroprotection mechanisms of action, as an antioxidant
agent, by reducing brain edema and inflammatory-related factors, controlling of
vasogenic edema through blood brain barrier (BBB) reconstitution and aquaporin-4
water transporter modulation, axonal regenerating stimulant, inhibition of inflam-
matory cytokines production, synaptogenesis and dendritic arborization, altering
glutamate receptor activity to reduce excitotoxicity of injury and also taking all
these effects by its receptor’s key rolling [14–16]. Also inhibition of ion flux cell
pores like L-type calcium channel, potassium, and sodium voltage-gates, as well
GABA-A receptors, all result in vasoconstriction and reducing edema that seem
likely to dihydropyridine’s mechanism of action, without its side effects like dizzi-
ness, peripheral edema, hypotension, reflex tachycardia and headaches [17, 18].
2.4 Monoaminergic agents
Amphetamine and other promotors of neuroaminergic neurotransmission have
been suggested to improve the functional recovery of the brain after TBI. There is
also a Cochrane review for these agents [19].
2.5 Erythropoietin (EPO)
A glycoprotein hormone of cytokine type-I super family, that its anti-apoptotic
and anti-inflammatory properties, also interaction of EPO with neural voltage-
gated calcium channels, and EPO with EPO-receptors increasing of local production
after TBI, seems to be EPO’s mechanisms of action [20–22].
2.6 Magnesium sulfate and other magnesium salts
Reduction in serum magnesium levels after TBI, and beneficial effects of mag-
nesium therapy in animal models, conceptualized its use for human cases, its failure
in recent studies, came to the conclusion of blood brain barrier (BBB) effect on this
agent’s transmission [23].
2.7 Cerebrolysin
“Cerebrolysin is a peptide-preparation, produced by the bio-technologically
standardized enzymatic breakdown of purified porcine brain proteins.”mechanism
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of action is not fully understood, but animal studies, suggest improved neuronal
oxygen utilization, reduction of cerebral lactic acid concentration and free oxygen
radical concentrations [24].
2.8 Citicoline (CDP-choline) and other cholinergics
Adenosine tri-phosphate (ATP) is responsible for cell membrane sodium-
potassium (Na-K) ATPase pump’s function; TBI related cell membrane un-integrity
and accumulation of extracellular water, leads to the known brain edema, also
formation of lipid peroxidase. Cholinergic agents’ effects in cell-oxygenation cycles
and formation of ATP indirectly may cause cell wall integrity formation as well as
prevent further secondary injuries [25].
2.9 NeuroAid
A Chinese medicine, also known as MCL601 and MCL901 (a.k.a. Simplified to
NeuroAid or NeuroAid-II, respectively), which showed Neuroprotective effects in
stroke trials [26, 27].
2.10 Cyclosporine A (CsA)
Preservation of mitochondrial function after TBI is the recommended mecha-
nism of action for this agent [28, 29].
2.11 Rivastigmine
Mostly known for its cholinesterase inhibitory (ChE-inh) effects, that improves
cholinergic function of brain in Alzheimer disease (AD) trials; there are also TBI
trials based on hypothesis of post-traumatic cholinergic deficiencies [30, 31].
2.12 Piracetam
This intervention seems to improve neurocognitive state of patients without any
remarkable effects on the mortalities.
2.13 Anti-epileptic drugs
Anti-epileptic drugs may have some Neuroprotective effects as well, but they
are not included in this study, however these drugs have their own Cochrane
review [3].
2.14 Why it is important to do this review?
The review, been performed on Neuroprotective agents for TBI, fulfill the
systematic review & analysis on each one of the mentioned agents in “Literature
Review” section of this study; “Drug data is complex and requires thoughtful
consideration regarding which medication and therapies are best suited for certain
situation and patients.” Leucht et al. declared [12]. Burns et al. work didn’t clearly
demonstrate the use of new stem cell studies on TBI, but it has hopes for SCI [9].
Studies showed people may not feel comfortable with stem cell therapies because of
“don’t want to get the risk of cancer” or “don’t want to have another surgery” who
also are about 58–63% of patients [9] that may lead our current hopes to neuro-
protective use, despite stem cells.
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3. Methods
Criteria for considering studies for this review.
3.1 Types of studies
The back-bone of present study’s meta-analyses made by including RCTs, which
their reporting quality, compared to CONsolidated Standards Of Reporting Trials
(CONSORT-statement) 2010 (http://www.consort-statement.org/); other related
to subject articles, with good and qualitative methods in reporting, included
according to the study’s statistical consultant’s point of view. Guidelines or pro-
tocols, letter to editors and systematic reviews are excluded from the data analyses.
3.2 Types of participants
Humans of any age, and with any severity (mild, moderate, severe) of focal or
diffuse TBI, have been included; neither animal studies nor pre-clinical (in-vivo)
trials included in this study.
3.3 Types of interventions
The related studies about the mentioned agents in “Literature Review” section
with any frequency, any chronicity and any mode of use.
3.4 Types of outcome measures
Outcomes were analyzed in two main groups for acute TBI management:
3.4.1 Primary outcomes
• Mortality and vegetative state
• Good recovery and mild disability
As measured by Glasgow Outcome Scale (GOS) or Extended Type (GOS-E)
after 3–6 months of patient follow-up; severe disabilities weren’t included in the
analyses.
3.4.2 Secondary outcomes
• Any adverse effects or events of interventions during the trial.
For chronic TBI management, outcomes were mostly analyzed for
neurocognitive state.
3.5 Search methods for identification of studies
The search strategy was not restricted by language, date, participants race,
gender or publication status; but date limitation implemented to the referencing
databases (i.e., SCOPUS and Thomson Reuters Web of Science) for after 2000
search results, also limiting results to human studies where possible.
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3.5.1 Electronic searches
The web-based searched data-bases are:
• Cochrane CENTRAL (September 6, 2015)
• MedLine through PUBMED (September 6, 2015)
• SCOPUS (September 6, 2015)
• Thomson Reuters Web of Science (September 6, 2015)
• SID.ir (September 6, 2015)
• Barekat Knowledge Deployment Foundation (formerly known as IRAN-
MEDEX) (September 6, 2015)
• ClinicalTrials.gov (September 6, 2015).
3.5.2 Searching other resources
Other related articles, came out through Internet search for full-text articles, and
full-text requests through www.researchgate.net, and skimming in bibliographies
of articles. Also contacting with experts to enrich the including data.
3.6 Data collection and analysis
Zotero v.4.0.28 (available from www.zotero.org) was used as Reference Man-
ager of this review, while Cochrane’s Review Manager (RevMan v5.3) taken the role
of meta-analyses and conducting the whole study as well.
3.7 Selection of studies
Screening of related articles via their titles and abstracts done by two review
authors (AM and MM); further assessment of including articles obtained by apply-
ing CONSORT-statement 2010 on full-texts of the articles by two review authors
(HSB and MM), also disagreements of the screening-phase articles and the decision
to include non-RCT studies referred to statistical consultant of study (HSB). The
Preferred Reporting Items for Systematic Reviews & Meta-Analyses (PRISMA)
statement, lead authors to diagram the process of study-selection (Figure 1).
3.8 Data extraction and management
Two review authors (AM and MM) extracted data from the included studies
using CONSORT 2010 characteristics; any disagreements, referred to the third
author (HSB).
3.9 Assessment of risk of bias in included studies
Two review authors (HSB and MM) assessed RCTs using the “risk of bias”
assessment tool of “Cochrane Handbook for Systematic Reviews of Interventions v.
5.1.0” [32].
6
Traumatic Brain Injury - Neurobiology, Diagnosis and Treatment
Figure 1.
PRISMA template (study flowchart).
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3.10 Measures of treatment effect
Glasgow Outcome Scale (GOS) or its Extended type used as the assessment tool
for severe TBIs outcome, considered to take place in the analyses; otherwise,
patients preference of interventions [i.e., patient reported outcome (PRO)] in
studies’ results, were taken as outcome measurements of included studies in mild
and moderate TBIs. More information of each intervention outcome analysis is
represented under “Results” section of the study.
3.11 Unite of analysis issues
All meta-analyses of fixed effects model for dichotomous quantitative results,
done by their risk ratio and confidence interval (CI) = 95%; continuous data results
analyzed by their mean difference and CI = 95%; random effects model applied if
I2 > 50% [33].
3.12 Dealing with missing data
According to search strategy, authors have to conclude as possible as the avail-
able studies for the review, reduce selection and information biases as well; but
some data would never been available even after contacting the original investiga-
tors or correspondence authors; the authors strategy for dealing with these kind of
missing data was to ignore the missing data and to analyze only the available data,
but if it’s assumed that the missing data, had a huge effect on the analysis, in the
HSB’s point of view, using statistical models to allow missing data in analysis,
making assumptions about their relationships with the available data were taken,
fortunately there was no such conflict during this study’s process.
3.13 Assessment of heterogeneity
Any heterogeneity of studies referred to HSB, for statistical consultant’s point of
view to reassess their use in the study, if they didn’t have the availability to take
part in study, they had been excluded.
3.14 Assessment of reporting biases
Probable reporting biases of studies, reported by using “Cochrane Handbook for
Systematic Reviews of Interventions v. 5.1.0” method [32].
3.15 Subgroup analysis and investigation of heterogeneity
Data analyses based on:
• Favorable outcome of intervention (mostly based on GOS or GOS-E);
• Mortality and vegetative-state analysis
• Probable side-effects of interventions.
If some interesting results of study(ies) are brought, they’d be analyzed
separately.
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3.16 Sensitivity analysis
All of the search studies results reporting, were based on significant meaningful
of results with p < 0.05 and CI = 95%.
4. Results
4.1 Description of studies
Qualitative report of study results, was completed with RCTs meta-analyses.
Which from 38 RCTs included in this study, 18 RCTs been meta-analyzed. Also
previous review papers in this field covered RCTs which are not included in this
review again, i.e., 27 of these RCTs were discussed by Alderson et al. Cochrane
review of corticosteroids [4]; Monoaminergic agents Cochrane review by Forsyth
et al. covered 20 of them [19]. However previously discussed papers in HBO2 and
NBH Cochrane reviews, didn’t take part in this review again [1, 2], which limited
oxygen topic’s studies to seven papers and no new articles found for those other two
topics; Figure 1 and Table 1 summarize the finding information. The 18 included
meta-analyzed studies, have a population of 4637 patients, of which 3650 patients
were for four new phase-III RCTs altogether. Furthermore information is available
under each topic of “Results of the search” section.
4.2 Results of the search
4.2.1 Oxygen
This intervention is the most eligible one of all other experimental trials of TBI
neuroprotectives. Two Cochrane reviews were conducted under the title
Neuroprotective Total no.
RCTs
No. RCTs
in this
study
No. RCTs
included
No. acute
TBI RCTs
No. chronic
TBI RCTs
Studies
populations
No.
phase-3
RCTs
Oxygen 24 7 4 1 3 205 0
Corticosteroid 27 All study results from Alderson 2006 Cochrane review [4]
Progesterone 7 7 4 4 – 2320 2
Monoaminergics 20 All study results from Forsyth 2011 Cochrane review [19]
Erythropoietin 4 4 2 2 – 645 1
Magnesium 4 1 Vink et al. [23] results combined with this pilot study 0
Cerebrolysin 1 1 1 1 – 32 0
Citicoline 4 4 4 3 1 1196 1
NeuroAid 0 0 0 0 0 0 0
Cyclosporine A 5 5 2 2 – 89 0
Rivastigmine 3 3 1 – 1 157 0
Piracetam 3 0 0 unknown unknown unknown unknown
Miscellaneous unknown 6 0 – – – –
Total 102 38 18 13 5 4637 4
Table 1.
Neuroprotective RCTs for TBI at a glance.
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“Hyperventilation therapy for acute traumatic brain injury (Review),” which
established in 1997 and continued till the last updated paper of 2009 [2], and
“Hyperbaric Oxygen therapy for the adjunctive treatment of traumatic brain injury
(Review),” which started from 2004 and was last revised in 2012 [1]. These reviews
demonstrated reduction in mortality rates while using oxygen in TBI, but there was
no adequate evidences to support better clinical outcomes. This review’s search
results got eight more new additional studies. One observational study to investi-
gate guideline adherence about pre-hospital advanced airway attempt for oxygena-
tion in 54 severe TBI patients, that resulted in good adherence of performers to the
guidelines [34], which also reported in other studies aimed to assess practitioners’
adherence to guidelines, even better if they were supported by strong evidences
[35, 36], but not satisfied results which recommended revision for guidelines; and
seven clinical trials, mostly case-sham control design method, that five of them
were pilot phase-II studies supported by Department of Defense/Veteran Affair
(DoD/VA) for a huge phase-III RCT on HBO2 use [37–41], the other two trials were
Rockswold et al. and Boussi-Gross et al. for combined HBO2/NBH treatment and
HBO2 in a case control and cross-over method trials respectively [42, 43]. Except
than Rockswold et al. study on acute TBI patients, other studies’ participants were
of chronic impaired TBI patients.
Overall patients analyses without loss to follow-ups are 205 patients as 48 in
Wolf et al., 42 in Rockswald et al., 56 in Boussi-Gross et al. and 59 in Cifu et al.; This
review, include all of these trials in narrative review, but because of their heteroge-
neity in reporting outcomes, no meta-analysis conducted for the results [37, 40,
42, 43].
The only study reported mortality was Rockswold et al. for 16% in HBO2/NBH
combined group and 42% in control group, that might be due to its acute phase
design for TBI management [43] in comparison to other three trials were about mild
chronic TBI management. Boussi-Gross et al. study reports significant improve-
ments in cognitive states (memory, attention, executive function, information
processing speed) of patients with mild TBI in chronic phase, while DoD/VA related
studies didn’t state any significant changes of cognitive functions between HBO2
and sham-control groups according to their Immediate Post Concussion Assessment
and Cognitive Testing (ImPACT) and Post-Traumatic Stress Disorder Check List-
Military (PCL-M) assessment tools [37, 40, 42]; Rockswald et al. acute phase study’s
GOS outcome for HBO2/NBH combined group, demonstrated significant improve-
ments (p = 0.024), and better outcomes for cerebral metabolism, partial oxygen
pressure in brain and ICP [43].
Also only side-effect report was in Wolf et al. study that ear barotrauma
and headache were the most common conditions [41], while Cifu et al. study on
eye tracking abnormalities didn’t demonstrate any significantly meaningful
improvements for HBO2 treatment participants, Wolf et al. results on Snellen
chart assessment of visual acuity showed improvements in both HBO2 and
Sham-control groups (22 of 47 eyes and 25 of 46 eyes respectively), also reduc-
tion of visual acuity was less in the sham-control group (6 of 47 eyes and 3 of 46
eyes) [39, 41].
4.2.2 Corticosteroids
Cochrane updated review for corticosteroids in 2006, recommended no more
trials of corticosteroids for TBI according to phase-III CRASH trial’s results, another
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update of this review at January 7, 2009, found no novel study to investigate. There
was no more study in current review’s search results too.
4.2.3 Progesterone
The 2012 Cochrane review of “Progesterone for acute traumatic brain injury
(Review),” based on three phase-II trials, declared that it would be updated as two
more multi-centric clinical trials’ results came out [5]; at the time of current
review’s searching for Neuroprotective agents, those mentioned trials and one more
study been achieved [10, 11, 44]. Authors complete reading each one of the studies
by comparing them to CONSORT 2010 checklist, finally included four studies
[10, 11, 45, 46] and excluded three of them [44, 47, 48].
Included studies consisted of 2320 cases (1192 in progesterone group and 1128
in placebo-control group); SYNAPSE study and ProTECT-III respectively by
Skolnick et al. and Wright et al. (in 2014) are the new phase 3, multi-centric,
RCTs with the weight of 93.5% of whole cases [10, 11]. ProTECT-III halted in its
secondary interim analysis, but SYNAPSE completed the predicted proposal and
consists 51.5% of cases.
The analyses of favorable intervention outcome and mortality in these studies
based on GOS report analysis in current method: favorably outcome (good
recovery and moderate disability), mortality (vegetative state and death), the
severe disability didn’t included in the analysis. All of these studies analyzed their
outcomes in a 6 month period but Wright et al. (in 2007), had a follow-up of
30 days [10, 11, 45, 46].
Intervention’s side-effects also analyzed as the most happened for patients in
each group as a whole but not on each of the side-effects solely. Also two studies
didn’t take part in this analysis. Skolnick et al.’s outcome results for adverse effects
were different from case-control group’s total number. It seems that five cases from
control group have been analyzed in case group. An E-mail has been sent to the
corresponding author for this confusing part, but till date, there is no reply [11].
Xiao et al. reported no adverse effects for the intervention [46].
The analyses showed no significant differences between progesterone and
placebo groups in favorable treatment [(p = 0.75; RR 1.02, 95% CI 0.88–1.19;
participants = 2320; studies = 4; I2 = 53%) Figure 2], neither in mortalities
[(p = 0.21; RR 0.77, 95% CI 0.50–1.17; participants = 2320; studies = 4; I2 = 82%)
Figure 3], nor in adverse effects analysis [(p = 085; RR 1.03, 95% CI 0.72–1.48;
participants = 982; studies = 2; I2 = 87%) Figure 4].
Figure 2.
Progesterone favorable outcome.
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4.2.4 Monoaminergic agents
The Cochrane review of “Monoaminergic agonists for acute traumatic brain
injury,” first established in 2006, and updated later on, till its last update was in
2011 didn't included any studies [19]. Search results didn’t collect any new studies.
4.2.5 Erythropoietin (EPO)
The primary search results for this topic, consists of a review on in-vitro and in-
vivo studies till 2009 [49]. One retrospective case-control study [50] and four
prospective RCTs [20, 22, 51, 52]; two of these studies were reports of a same phase-
III multi-centric placebo-control trial known as EPO-TBI, and Nichol et al.’s
reporting was more complete than the other one, which persuades authors to
exclude Presneil et al. from quantitative analysis [21, 22]. Abrishamkar et al.’s paper
has been excluded from meta-analysis too, due to its restricted study design on male
patients [20].
The whole studies population analysis related to Aloizos et al. and Nichol et al.
were 645 patients [21, 51]. Both studies followed patient up to 6 months analyzing
total better outcomes of patients showed no significant difference between study
groups [(p = 0.30; MD 1.22, 95% CI 1.09–3.53; participants = 638; studies = 2;
I2 = 99%) Figure 5], also EPO-TBI trial’s GOS reporting outcome showed no signif-
icant difference too [(p = 0.90; RR 1.01, 95% CI 0.87–1.17; participants = 596;
studies = 1; I2 = 0%) Figure 6]. Mortality and vegetative-state analysis, was signif-
icantly skewed toward intervention group [(p = 0.04; RR 0.65, 95% CI 0.43–0.98;
participants = 644; studies = 2; I2 = 0%) Figure 7]; while side-effect analysis showed
nearly significant less vascular side effects in intervention group [(p = 0.06; RR
0.86, 95% CI 0.73–1.00; participants = 603; studies = 1; I2 = 100%) Figure 8] and no
significant difference in non-vascular side-effects between two groups of EPO-TBI
Figure 3.
Progesterone mortality.
Figure 4.
Progesterone adverse-effects.
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trial [(p = 0.73; RR 0.93, 95% CI 0.62–1.39; participants = 603; studies = 1; I2 = 0%)
Figure 9], there was no side effect report in Aloizos et al. [51].
4.2.6 Magnesium sulfate and other magnesium salts
An updated review on magnesium, published in 2009 [23]; and no new studies
been established in current review’s search results after that timeline, the only study
which was not mentioned in Vink et al. paper, was a pilot study on pediatric
population with severe TBI, to maintain magnesium’s feasibility and bio-availably
for this population [52]. The common result of these studies, could be summarized
Figure 5.
Erythropoietin total outcome assessment.
Figure 6.
Erythropoietin favorable outcome.
Figure 7.
Erythropoietin mortality.
Figure 8.
Erythropoietin vascular side-effects.
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as despite pre-clinical in-vivo studies of magnesium concentration in cerebrospinal
fluid (CSF), that decline after acute TBI, and magnesium administration enhances
its disposition in this field; no BBB feasibility seen in human studies for magnesium,
and predicted mechanisms of actions for this intervention on human-beings are out
of clinical evidence support [23, 52].
4.2.7 Cerebrolysin
There was a cohort-study by Wong et al. and a phase-II RCT by Chen et al. for
cerebrolysin use in the search results [24, 53], also an ongoing huge multi-centric
study held from third quarter of 2015 as well [54]. Cohort study, followed 42
patients with moderate to severe TBI, in 1:1 ratio, and report the outcomes in GOS
scale after 6 months, which resulted in 67% good outcomes with cerebrolysin:
placebo ratio of 19:14 in both study groups. The RCT reported cognitive outcomes
with Mini-Mental Status Examination (MMSE) and Cognitive Abilities Screening
Instrument (CASI) scales for mild TBI patients after 3 months that showed signifi-
cant favorable outcome in intervention group [(p = 0.02; MD 13.40, 95% CI
24.87 to 1.93; participants = 32; studies = 1; I2 = 0%) Figure 10].
4.2.8 Citicoline (CDP-choline) and other cholinergics
Articles related to citicoline intervention published from 1991–2014 [55–58].
Zafonte et al.’s study was a huge multicentric study a.k.a. COBRIT (citicoline brain
injury treatment) and halted in its forth interim analysis due to non-significant
outcome differences between placebo and intervention groups, but patients
followed up to 180 days after injury, that 180 day’s results are included in this
review’s analysis. Maldonado et al. and Shokouhi et al. studies didn’t have placebo
group, they were case-control studies, both included patients with severe or mod-
erate acute TBI (216 and 58 patients respectively) [56, 57]. Leon-Carrion et al. study
was a limited RCT of 10 patients for assessing neurocognitive effects of citicoline
[55]. COBRIT planned to enroll 1292 patients, which halted in its forth interim
analysis with 1213 patients randomized in two placebo and citicoline groups, the
Figure 9.
Erythropoietin non-vascular side-effects.
Figure 10.
Cognitive changes for cerebrolysin.
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primary outcome assessment on day 90 of patients, was available for 996 cases,
while 180-day outcome enrolled 902 cases [58].
In total, this meta-analysis included four studies with 1196 patients, which
COBRIT study weighs about 75% of the analysis. The starting citicoline dose in
studies was 2 g/day in Zafonte et al. and Shokouhi et al.’s trials, 1 g/day in Leon-
Carrion et al.’s study, and 4 g/day in Maldonado et al.’s (that reduced to 3 g/day
after day 3–4 of intervention and 2 g/day in case phlebitis would recognized).
Meta-analysis of outcomes showed no significant change in GOS outcome
[(p = 0.76; RR 1.03, 95% CI 0.86–1.24; participants = 1128; studies = 2; I2 = 71%)
Figure 11], but significant favorable of neurocognitive changes in placebo-control
group despite studies heterogeneity [(p < 0.00001; SMD 1.00, 95% CI 0.75–1.25;
participants = 971; studies = 3) Figure 12]. However the comparison of COBRIT
study’s days-90 and 180 GOS outcomes, demonstrated improvements in day 180
outcomes [58]. Mortality and vegetative-state outcomes were analyzed together in
studies, which only two studies (Maldonado et al. and Zafonte et al.) reported these
outcomes with no significant difference [(p = 0.96; RR 0.98, 95% CI 0.51–1.86;
participants = 1429; studies = 2; I2 = 67%) Figure 13]. The side-effects of interven-
tion at all has no significant difference between trial groups either [(p = 0.53; RR
1.03, 95% CI 0.94–1.12; participants = 1429; studies = 2; I2 = 57%) Figure 14].
4.2.9 NeuroAid
There was no trial for NeuroAid use in TBI.
4.2.10 Cyclosporine A (CysA)
Search strategies results, brought five articles for this topic; and all were pro-
spective clinical trials, Brophy et al., Empey et al., and Mazzeo et al. (in 2008)
reported and analyzed Cyclosporine’s concentration and safety dose for human use
Figure 11.
Citicoline favorable outcome (GOS results).
Figure 12.
Citicoline favorable outcome (at all).
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were [28, 59, 60]. The other two papers’ population been analyzed at all were 89
patients [29, 61]. Cyclosporine’s favorable GOS outcome analysis showed no signif-
icant difference between two interventional and placebo groups [(p = 0.83; RR 1.28,
95% CI 0.14–11.86; participants = 75; studies = 2; I2 = 65%) Figure 15]; either there
was no significant difference in mortalities [(p = 0.76; RR 1.17, 95% CI 0.443.12;
participants = 89; studies = 2; I2 = 0%) Figure 16] but CysA had significant effect on
ICP control, and less ICP rise in comparison to placebo [(p = 0.01; RR 0.70, 95% CI
0.53–0.92; participants = 89; studies = 2; I2 = 39%) Figure 17].
4.2.11 Rivastigmine
Three articles were related to this intervention in search results [30, 31, 62].
Silver et al. [31] was the continuation follow-up of Silver et al. [30] trial, which all
placebo and rivastigmine group of 2006 study, got through rivastigmine interven-
tion for 26 extra weeks, the results of this article, didn’t differ significantly from the
last report, so the 2009 study was excluded from the analysis; Tenovuo’s study was
Figure 13.
Citicoline mortality.
Figure 14.
Citicoline side-effects.
Figure 15.
Cyclosporine favorable outcome.
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an out-patient clinic practice on 111 patients with three ChE-inh (Rivastigmine,
Galantamine, and Donepezil), randomly assigned to patients by author, was
excluded because of no placebo group, no blinding allocation statement and no
obvious concealment reporting. Which all of these three articles lead results
reporting to Silver et al. [30] trial, with 157 randomized patients in 77 placebo and
80 rivastigmine groups.
Silver et al. [30] study, has no mortality report in cases, but patients whom
completed 12 weeks of trial time-line, were 70 in rivastigmine and 64 in placebo
groups, also three patients in total lost to follow up (one in rivastigmine and two in
placebo group); There was no significant difference for favorable outcome results
of this intervention in comparison to placebo [(p = 0.80; RR 0.96, 95% CI 0.69–1.33;
participants = 143; studies = 1; I2 = 0%) Figure 18]. But authors stated that
rivastigmine was efficient for more severe impaired patients in both 2006 and 2009
reports [30, 31]; it was analyzed as a sub-group analysis of 25% of patients and its
raw results were not declared in the studies. Side-effect analysis show no meaning-
ful difference too [(p = 0.74; RR 1.04, 95% CI 0.84–1.27; participants = 157; stud-
ies = 1; I2 = 0%) Figure 19].
Figure 16.
Cyclosporine mortality.
Figure 17.
Cyclosporine side effects (ICP rise).
Figure 18.
Rivastigmine favorable outcome.
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4.2.12 Piracetam
Search results brought following three titles for this intervention “Clinical Eval-
uation of Nootropil (Piracetam) in Severe Craniocerebral Injuries,” “Clinical trial of
piracetam in disorders of consciousness due to head injury,” and “A controlled
clinical study piracetam V. Placebo in disorders of consciousness due to head inju-
ries” but there was no achievement to their full-texts. However attempts to contact
authors had no success too.
4.2.13 Miscellaneous findings
There were review-like studies and RCTs, further than these 12 categorized
neuroprotectives, for TBI management, that a quick review of them proceeds in the
following paragraphs
a. A 2013 “meta-analysis of treating acute traumatic brain injury with calcium
channel blockers,” of nine RCTs, showed slightly better outcome of placebo
group, but it was not statistically significant (p = 0.52; RR 1.18, 95% CI 0.72–
1.95; participants = 171; studies = 2; I2 = 52%), however there was no significant
difference between intervention and placebo groups in mortalities (p = 0.44;
RR 0.93, 95% CI 0.77–1.12; participants = 1337; studies = 5; I2 = 0%), nor
adverse effects (p = 0.33; RR 1.11, 95% CI 0.90–1.37; participants = 1358;
studies = 4; I2 = 0%) [63]. The former hypothesis of “The role of mitochondrial
calcium uni-porter in neuroprotection in traumatic brain injury” may be
disclaimed as a result of this meta-analysis [64].
b.A parallel study to COBRIT “Early trajectory of Psychiatric Symptoms after
Traumatic Brain Injury: Relationship to patient and Injury Characteristic,”
show overall an improvement process of psychiatric characteristic of TBI
patient over 180 days assessment, with better outcomes on days 30–90; better
outcomes of female participants in comparison to males; not statistical
significant but Hispanic’s most and African-American’s least improvement
process in comparison to whites as the ethnic/race analysis’ reference group [65].
• Better significant emotion recognition training outcome by the mean of
11 years after TBI in facial affect recognition better than participants of
stories group in comparison to control group, showed impaired cognitive
abilities improvement in moderate to severe TBI patients in “A
randomized controlled trial of emotion recognition training after
traumatic brain injury” [66]; however hypothetical testing of stories
group to assess their ability to infer and label their feelings in given
Figure 19.
Rivastigmine side effects.
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scenarios, showed significant improvements. Patients responses to these
emotional recognitions, was not favorable, as authors recommend further
studies to instruct participants on how to response too [66].
• Hyperthermia after acute TBI, significantly results in unfavorable
outcomes and mortality rates of especially severe head injured patients
[67]; a Cochrane review of “Cooling for cerebral protection during brain
surgery” didn’t show significant result for this intervention [68], which
might be due to different purposes of studies.
• And Finally a before-after clinical trial of 35 patients for “Effect of light
music on physiological parameters of patients with traumatic brain
injuries at intensive care units” using Dr. ArndStein’s 70–80 metronome
rhythmic melody, showed better significant physiologic outcomes in
decreasing systolic and diastolic blood pressure, pulse rate, respiratory
rate, arterial blood pressure and body temperature and increasing arterial
oxygen saturation (<0.001); however pulse pressure decreasing was not
significant [69].
4.2.14 Risk of bias in included studies
As a whole, “randomization part” of studies has a good assessment overall;
however “allocation concealment” or “how blinding participants or personnel take
place” didn’t seem to be well reported. Finally RCTs reporting didn’t accommodate
well enough to CONSORT statement (i.e., this review study’s tool for analyzing
study reports). Figures 20 and 21 are at a glance quick look assessment of risk of
bias in included studies.
4.2.15 Effects of interventions
Overall, by the analysis of only phase-III studies results, no significant difference
seen between neuroprotectives and placebo groups in favorable outcomes
[(p = 0.30; RR 0.97, 95% CI 0.90–1.03; participants = 3560; studies = 4; I2 = 0%)
Figure 22]; or mortalities [(p = 0.51; RR 0.92, 95% CI 0.73–1.17; participants = 3876;
studies = 4; I2 = 52%) Figure 23].
Figure 20.
Risk of biases graph: review author's judgments about each risk of bias item presented as percentages across all
included studies.
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Figure 21.
Risk of biases summary: review author's judgments about each risk of bias item for each included study.
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5. Discussion
5.1 Summary of main results
5.1.1 Oxygen
Despite other trials of oxygen intervention in acute phase TBI, Rockswald et al.
study’s new design in combination of HBO2/NBH, rather than solely attempt of each
one results in better and significant outcomes [43]; it could be a new recommenda-
tion for future trials of acute phase TBI management, as its mortality report was the
same as past trials, but with better GOS outcome [1, 43].
Boussi-Gross et al. study’s improvement results in cognitive function of mild
chronic TBI patients despite other DoD-/VA-related studies’ results may be due to
differences in civilian and service member populations of each study design, prob-
able posttraumatic syndrome disorder (PTSD) symptoms of DoD/VA members,
and different assessment tools; also, controversies of eye problem conditioning
between Cifu et al. and Wolf et al. may resolve in a large group study with a
common manifest of study objectives and participant evaluation [37, 38, 40–42].
In conclusion, there were lots of controversies between oxygen phase-II trials till
now, but no multi-centric phase-III trial been conducted for this intervention, the
one is strongly recommended also in a normal population and not just for DoD/VAs
[41]. A Trial of HBO2/NBH—(sham) control design may have most cost-
beneficence than other kinds of solo intervention trials especially in acute phase TBI
management [43]. Using oxygen (especially HBO2) in chronic management of TBI
has no enough evidences yet.
Figure 22.
Phase-III neuroprotectives favorable outcome.
Figure 23.
Phase-III neuroprotectives mortality (CRASH 2005 not included).
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5.1.2 Corticosteroids
CRASH study’s results that weigh about 95% of the Alderson’s Cochrane review
in “Corticosteroids for acute traumatic brain injury—last revised 2009,” made the
fact of increasing mortalities in TBI, by using corticosteroids [4]; no new trials
found on steroids effect for TBI after these papers.
Current review’s applicability on using corticosteroids for CNS acute traumas,
leads to another Cochrane review of “Steroids for acute spinal cord injury—last
revised 2012” [13]; however these conditions (TBI and SCI) may coincide (dual-
diagnoses). So what are the practical recommendations for these situations?
According to Bracken’s review “Methylprednisolone sodium succinate must be
started within 8 hours of injury, using an initial bolus of 30 mg/kg by IV for
15 minutes followed 45 minutes later by a continuous infusion of 5.4 mg/kg/hour
for 24 hours. Further improvement in motor function recovery has been shown to
occur when the maintenance therapy is extended for 48 hours. This is particularly
evident when the initial bolus dose could only be administered 3–8 hours after
injury”; dosage and limited time of intervention for SCI patients, mentioned in the
review by contemplate of situations with cohesion of TBI and SCI literally 16–59%
[70], therefore challenging decision making on using corticosteroids (especially
Methylprednisolone, as recommended in the review) on these conditions needs
awareness of reviews results combination. It’s suggested to use the recommended
methylprednisolone protocol for dual-diagnose patients only in the initial bolus
dose timing of 3–8 hours after acute injury, following therapy for only 48 hours;
neither other corticosteroids nor extensive use of this protocol, are not suggested or
acceptable for dual-diagnose patients management, also Nott et al. study brings
hopes in cognitive behavior of dual-diagnosed ones [70], that discussed by social
effects of condition in the study, this may persuade health-care practitioner and
cost-benefit analyst about using this intervention for dual-diagnoses.
5.1.3 Progesterone
SYNAPSE and ProTECT-III trials results for progesterone, changed the former
vision of this intervention’s effect on TBI management, as CRASH trial did for
corticosteroid in 2005.
Progesterones are gonadal steroids, and assume to have been more favorable in
neurodegenerative disorders like multiple sclerosis (MS), Alzheimer disease (AD),
and maybe TBI, i.e., neurodegenerative effects of microglia after injury and induced
inflammatory response in whole body [14, 16, 71], as mentioned by Beyer [15].
Leucht et al. and Burns et al. studies results are good challenging statements for
current visions of pharmaceutical interventions for major chronic disorders and
central nervous system (CNS) injuries respectively [9, 12]. The pharmaceutical
interventions failure in huge phase-III trials for TBI in the last decade (i.e., from
CRASH 2005 to EPO-TBI 2015), even as smoothly penetration of progesterone
through BBB to take its promising effects in pre-clinical studies [10, 11, 14, 15,
17, 18], made this statement from Wright et al. who designed and proceed three
trials of progesterone use in TBI [10, 45, 47] “Despite these design strategies and
extensive efforts, the trial did not confirm the efficacy of progesterone in patients
with acute TBI. It is possible that the heterogeneity of the injury, confounding
preexisting conditions, and characteristics of individual patients (e.g., resilience),
which can be well controlled in animal models, play too large a role to overcome in
human disease. Approaches are needed to reduce heterogeneity, but they come at
the cost of more homogeneous pathological findings and decreased generalization
of the results. Success at translating from bench to bedside may require new
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paradigms, including innovative clinical-trial methods (e.g., adaptive designs and
profiling of patients who have a response) in early-phase clinical trials to identify
effective drug doses and timing (e.g., pre-hospital administration), the use of
targeted outcomes based on the mechanism of injury, and rigorous preclinical
multicentric trials in animals that better simulate subsequent human trials and
make more accurate predictions regarding results.” [10] “From Bench to Bed,”
“FromMice to Mind”; these statements declare incompatibility of basic studies with
clinical trials; the basic science consortium approach, is one of good options for
pharmaceutical intervention selection on human beings trials, it’s on the way, as
part of Combat Casualty Care Research Program-Operational Brain Trauma Ther-
apy Consortium [11].
Concluding all these results together, may associate the future attempts on
medicine to cellular-molecular field of bio-medicine in all of its era, as well as
trauma management [9]. Review results should declare that using progesterone in
the recommended I.V. doses has no significant beneficial effects than placebo;
recommendation of using progesterone for pediatric patients in TBI insults [16], has
no proof, as there is no structured RCT for that, and this age group’s recovery of TBI
effects, may naturally take place with controlling the damage by current guidelines.
“Combination therapy of 17-Beta-E2 and Progesterone while applying a basis of
Emulsion I.V. together with Omega-3 fatty acids, using high short-term dosages of
treatments rather than normal long-term treatments” mentioned by Beyer as
request of expertise-comment for his interests and experience since 1988 on
Gonadal Steroids use for CNS problems [15] may present the clue for further
researches in this field. Combination therapy of progesterone and vitamin D, espe-
cially in aged TBI patients [10, 14] is not proved in human cases, and beneficence of
this combination recommended therapy, might be questioned for not significant
efficacy of progesterone use in lately human phase-III RCTs; however another RCTs
should hold for vitamin D use for TBI patients to verify this statement.
5.1.4 Monoaminergic agents
Cochrane review for this topic didn’t include any articles, also there was no new
studies in this review’s search results too, and as they recommended in their article
“in the absence of clear evidence of benefit from Neuroprotective drug use, there is
an urgent need to explore other potential modulators of late outcome from TBI. The
reported results of these studies require replication in larger studies, extended to
other groups including more severely injured patients, and children” would be the
clue of further researches and trials.
5.1.5 Erythropoietin (EPO)
The total analysis and results of this topic demonstrate that, it reduces mortality
rates but no significant efficacy of EPO rather than placebo or control groups is
noted; also EPO-TBI resulted in side-effects, which didn’t report in other two trials
[20, 21, 51], that might be due to EPO-TBI’s higher EPO dose use (40,000 IU up to
3 doses) in comparison to 10,000 IU for 7 days of Aloizos et al. and 1000 IU in
6 doses during 2 weeks of Abrishamkar et al. There were side effects in placebo
group of EPO-TBI trial too; that challenges this statement. Nearly significant better
outcome of side-effects for EPO group in Nichol et al. EPO-TBI trial is far away
from last expectations of EPO trials [21, 49] that confirms Leucht et al. statement on
drugs complexity effect [12]. All three trials administered the intervention through
subcutaneous (S.C.) route, as Abrishamkar et al. declared, despite LAB trials, it’s
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nearly impossible to gather Intra-Ventricular route for agent administration in
edematous TBI brain [20].
Final conclusion on this topic, otherwise its prospective phase-III multi-centric
placebo-controlled RCT, cannot obviously be presented, due to different dose of
interventions between studies (i.e., more than recommended does 1000–30,000 IU
in EPO-TBI trial [21, 51]; better outcomes in mortality-rate and side-effects reduc-
tion for intervention group; But overall, it showed better outcome in placebo group,
which makes the clinical decision-making a challenge on using EPO for acute TBI.
It should be recommended to conduct another prospective phase-III multi-centric
placebo-controlled RCT with intervention dose of no more than 30,000 IU during
EPO-administration to conduct better decision about choosing this intervention
wisely for acute TBI assaults.
5.1.6 Magnesium sulfate and other magnesium salts
Magnesium beneficence for human beings through its CSF concentration didn’t
proved with the former trials, and Vink et al. reported the fact in 2009 [23]. Further
trials on magnesium concentration in CSF may conducted via its administration
through Intra Ventricular route, to find out its probable Neuroprotective effect,
however it seems not to be successful [20].
5.1.7 Cerebrolysin
Limited evidences for this intervention’s effect on TBI patients, also in different
severities of TBI, mild TBI in RCT study and moderate to severe TBI in cohort study
[24, 55], couldn’t investigate its reliability for generalized use recommendation in
TBIs; Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery
(CAPTAIN) results [54] is going to lead the future responsibilities and decisions to
use this intervention in TBI situations.
5.1.8 Citicoline (CDP-choline) and other cholinergics
COBRIT study for citicoline seems to be like CRASH, SYNAPSE and ProTECT-
III or EPO-TBI, as it was a huge multicentric placebo-control RCT of citicoline, its
halt in forth interim analysis, may resulted to less participant of patients in follow-
up process, but it was none of significantly difference between groups’ analysis,
overall assessment of outcomes didn’t demonstrate any significant effect of
citicoline favorable especially in GOS, yet in COBRIT study’s assessment of GOS for
day-90 and 180, improvements are slightly better but not significant at all (from
p = 0.97 to p = 0.43), there is significant improvement of placebo-control group
patients in neurocognitive state rather than intervention group. Yet neither mortal-
ity nor side-effects of intervention versus control groups were significant.
Maldonado et al. study was the more notable one after Zafonte et al. COBRIT in
these search results; this study, Leon-Carrion et al. and Shokouhi et al. studies’
beneficence in citicoline use for severe and moderate TBIs, questioned by COBRIT
overall outcomes both in day-90 and 180 outcomes [55–58]. Also a significant better
outcome change was obvious in mildly complicated cases on day-180 outcome in
COBRIT study [58]. Heterogeneity of intervention doses and outcome assessments
in included studies surrounded by Zafonte et al. Study’s results; though current use
of citicoline for TBI in acute or chronic phase, is no more recommended by the
results of this review, however it may have neurocognitive beneficiaries for mild
TBI, that decision of using this experiment on these conditions, belongs to attending
physician’s opinion and other assessments.
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5.1.9 NeuroAid
Trials on Neuroaid for brain injury conditions mostly studied its effects on
stroke brain injuries; none of current study’s search results, related to Neuroaid use
in TBI; that may suggest the clue for future trials.
5.1.10 Cyclosporine A (CysA)
Cyclosporine A’s use may prevent ICP rise or reduce it, in comparison to placebo
as this analysis showed. However there is no significant effect of its use in 6-month
favorable outcomes or mortality rates. Also cohort study groups of Hatton et al. and
other drug concentration studies confirm that best blood and cerebrospinal fluid
(CSF) CysA depositions resulted from its high doses and fortunately the wide
therapeutic window [28, 59–61]. Both of the included studies have a 5 mg/kg
intervention on their design protocols, also Hatton et al. recommended a 2.5 mg/kg
bolus dose in 2 hours of TBI insult following by 5 mg/kg/day for 72 hours, as optimal
dosing strategy for further clinical trials study design. As there would be a huge
multi-centric, prospective, phase-III RCT for CysA after National Institute of
Health (NIH) proves its proposal [29]; that might bring future evidences on using
this intervention for TBI (especially acute) management.
5.1.11 Rivastigmine
Rivastigmine and other ChE-inh use for TBI, mostly known for their cognitive
behavioral effects, and their trials take part in chronic TBI managements, Tenovuo’s
study didn’t show a significant difference between three drugs that patients
assigned to use, but mostly preferred Galantamine for its fewer side effects [62].
Silver et al. (both 2006 and 2009 studies) with 157 patients and better study design
in comparison to Tenovuo’s, didn’t show significant difference of rivastigmine and
placebo groups at all, but in severe impaired patients. These results support the
need of more RCTs especially multi-centric phase-III RCTs of rivastigmine and
other ChE-inh for chronic TBI management in severe impaired patients, the
recommended protocol as Silver et al. Stated, is to start with 3 mg of rivastigmine/
day and slowly increase to maximum dose of 12 mg/day if the previous dose was
well tolerated for at least 4 weeks. Routine use of rivastigmine for chronic TBI
management is not recommended, as it has no significant effect for patients rather
than placebo, as current evidences declared.
5.1.12 Piracetam
There were studies for this intervention but no achievement to their full-texts, it
may be one of this review’s reporting biases, which no clinical judgment may
presented for this intervention.
5.1.13 Miscellaneous findings
Following statements are recommendations for “Miscellaneous Findings” sec-
tion of “Results” section of the study:
• Improvement in psychiatric assessments of TBI patient, after assault differ
between individuals, there should be supportive psychological first aid (PFA)
tools for primary survivors of the assault; a Johns Hopkins University’s course
of PFA-RAPID which stands for Rapport and Reflective Listening, Assessment
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of Needs, Prioritization, Intervention, Disposition; is available at https://www.
coursera.org/course/psychfirstaid to triage and primary effective intervene of
health-care providers for trauma assaults survivors, as further than the insult,
sub-acute complications during recovery of patients, especially in two-third of
severe impaired TBI patients [72], may have affects on their family’s life too.
• Cerebral and body cooling for acute TBI impaired patients, may have better
outcomes in patients survival and reducing mortality rates, due to significant
unfavorable outcomes and mortality rates of high fevered patients after acute
TBI in Li et al. study; a strong evidence of phase-III multi-centric international
RCT, needed to prove this statement.
• Music-therapy use for TBI patient, seem to have better outcomes in physiologic
parameters, however other double-blinded RCTs need to prove this statement.
However Maleki et al. study’s aim was not to assess participants outcomes; as
well actual efficacy of this intervention on patients outcomes, might took
under survey too [9, 73, 74].
5.2 Overall completeness and applicability of evidence
All of RCTs checked with CONSORT 2010 checklist; the applicability of this tool
for further analysis of probable biases from participant randomization to outcome
report used on each of the included studies as well.
5.3 Potential biases in the review process
Primary database search strategy, didn’t consist interventions as search key-
words separately, the consultation with a medical librarian, persuade authors to
revise the strategy with search of Piracetam, NeuroAid and Citicoline (as commonly
used Neuroprotectives in their tertiary center, and for meta-analysis purpose of
these interventions), the re-run search strategy added few (about 7–10) records in
each database search, that skim review on their title and abstracts (duplicated
records, assessed with Zotero reference manager software for exclusion), didn’t
show significant change of eligible studies, and further search on all interventions as
solo keywords, didn’t take place. Current meta-analyses based on second search
strategy results. This may be a selection bias of this study and future reviews should
be aware of this bias; another probable bias in this review was in reporting out-
comes and mortalities analyses; Authors decide to report GOS or GOS-E outcomes
analyses in two groups: (1) favorable outcome, which consists of good outcome and
mild disability (GOS 4,5 and GOS-E 5-8) outcome; and (2) mortalities, that
reported vegetative state and mortalities analysis (GOS 1,2 and GOS-E 1,2). Some of
the articles, reported severe disability, vegetative-state and mortality outcomes
together; if it was possible to get special reports on outcomes, analyses get through
them, but if not, they’d been analyzed as the original article’s authors decision.
5.4 Agreements and disagreements with other studies or reviews
This review was a brand-new in interventions analyses for TBI (mostly acute)
management; other previous reviews based on significant intervention’s effect
analysis; some parts of this review used the former reviews or meta-analyses results
conducting new one, are referred through the text.
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5.5 Final pluralization
Overall conclusion of these results and outcome findings of neuroprotective
agents for traumatic brain injury management could be summarized as follows:
a. Oxygen using for acute management of TBI to reduce mortality rates is
obvious, however no significant change seen in favorable outcomes, if a setting
has HBO2 resource available, combined use of HBO2/NBH, may have better
patient outcomes than using HBO2 or NBH solely; recommended approach for
this facility is “combined HBO2/NBH treatment, which consisted of 100% FiO2
delivered for 60 minutes at 1.5 ATA followed by 3 hours at 1.0 ATA” [43]; also
there is no significant evidence for using HBO2 in chronic TBI management.
b.Corticosteroid use in solo acute TBI management is prohibited, as its increased
risk of mortalities; in dual-diagnosed patients (TBI and SCI together),
corticosteroid use, should be obtained by this protocol [13]:
i. patient came through 2–3 hours after assault (if longer, should not be
obtained)
ii. only methylprednisolone (other corticosteroids, has no beneficent effect
in SCI management) with following protocol should be administered
through IV route:
• Bolus dose: 30 mg/kg in 15 minutes,
• Following drip of: 5.4 mg/kg/day for the next 24–48 hours.
c. Current routine use of citicoline in acute TBI is no more supported, while no
significant difference in comparison to placebo been reported. Citicoline use
for managing neurocognitive conditions of chronic TBI, depends on attended
physician’s evaluation of patient’s condition and local setting’s evidence based
medicine (EBM) community’s decision. Rather its probable benefice in mild
TBI patients, it’s not recommended for all severity of TBI, while significant
improvements seen in placebo group.
d.Using of Cyclosporine A for ICP control, depends on the setting’s available
resources, and attending physician’s point of view, there is no other significant
difference for its favorable outcome in comparison to placebo. it should be
recommend to administer through IV route by following protocol in acute TBI
management [61]:
i. Bolus dose: 2.5 mg/kg in 2 hours,
ii. Following drip of: 5 mg/kg/day for the next 72 hours.
e. Rivastigmine use for chronic TBI management of neurocognitive conditions,
had some beneficence in severe impaired participants through phase-II trials of
3 mg/day and slowly increasing to 12 mg/day by adding 1.5 mg/day to previous
dose if tolerated for 4 weeks of last dose [30].
f. Other neuroprotective agents use for acute or chronic management of TBI, has
no field of support yet.
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6. Conclusions
6.1 Recommendations for practice
To use oxygen in acute management of TBI in order to reduce mortality rates
seems to be obvious, however no significant change seen in favorable outcomes;
corticosteroid use in solo acute TBI management is prohibited, as it increases risk of
mortalities, however in dual-diagnosed patients (TBI & SCI together), corticoste-
roid use, should be obtained by a protocol introduced by Bracken et al. Current
routine use of citicoline in acute TBI is no more supported, while no significant
difference in comparison to placebo been reported. Cyclosporine A usage for ICP
control, depends on the available resources, and attending physician’s point of view;
Rivastigmine use for chronic TBI management of neurocognitive conditions, had
some beneficence in severe impaired participants. However other Neuroprotective
agents use for acute or chronic management of TBI, has no field of support yet and
they needed more researches and trials.
6.2 Recommendations for research
Lastly phase-III RCTs for TBI management, change the former evidences of
Neuroprotective agents use (i.e., CRASH 2005 for corticosteroid [4], COBRIT 2012
for citicoline [58]. SYNAPSE 2014 [11] and ProTECT 2014 [10] for Progesterone
and EPO-TBI 2015 for erythropoietin [21]; despite current process of phase-I to
phase-III (IV) new drug evaluation to use in human-beings, it should be
recommended to skip phase-II trials for TBI related studies; heterogeneity of the
condition, make its accurate interpretation so difficult in restricted single-centered
phase-II trials. Scheduling large double (or more)-blinded huge multi-centric inter-
national phase-III RCTs, including low-income countries too as recommended by
Menon in “Unique challenges in clinical trials in traumatic brain injury” [75], with
acceptable design of interim analyses for number needed to harm (NNH) and
number needed to treat (NNT) at regular checkpoints, seem to have more accuracy
and cost-beneficent effects than current known processes. There was no strong-
evidenced well-designed trials for these interventions:
• Combined therapy of HBO2/NBH
• Monoaminergics;
• “High-dose, short-time administration of progesterone with 17-Beta-E2 in
emulsion of Omega-3,” as an expert advice for future studies [15] rather than
SYNAPSE and ProTECT results;
• Administering magnesium solutions via Intra-Ventricular or other achievable
routes in TBI patients for rising its concentration in TBI patient’s CSF;
• Rivastigmine use for chronic management of severe impaired neurocognitive
conditions;
• Cerebral or body cooling, especially in severely impaired patients of acute TBI
assault.
Also a Cerebrolysin phase-III trial is in the ongoing-list of current study [54].
And despite NeuroAid’s trials for stroke injured brain, there was no trial (even
phase-II) of this intervention for TBI.
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Cellular-molecular experiences in CNS conditions, has not been provided
acceptable outcomes for TBI to date, but as a recommendation of an expert “there is
potential for TBI” as “mirror pathophysiology of some of the other conditions,”
despite “the lack of sensitive outcome measures” there is hope to “promote at least
some improvement in recovery of function via immunomodulation and promoting
plasticity” [9].
It’s also recommended for RCT authors to use CONSORT-assessment guidelines
in their study designs and paper reports; and report clinical outcomes of mild,
moderate and severe suffered acute TBI patients in separate subgroup analyses,
which an eight-pointed GOS-E reporting scale is preferred to five-pointed GOS one
[75]; till better outcome assessment tool been developed; however studies on
hypotheses of drugs concentration in serum, or assessing physiological parameters
of patients; resulted in no more significant outcome of TBI patients in large phase-
III studies.
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